Insider Buying: Paradigm Biopharmaceuticals Limited (ASX:PAR) Insider Buys 150,000 Shares of Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Matthew Fry bought 150,000 shares of Paradigm Biopharmaceuticals stock in a transaction dated Thursday, October 10th. The stock was purchased at an average price of A$0.20 ($0.14) per share, with a total value of A$30,450.00 ($20,300.00).

Paradigm Biopharmaceuticals Price Performance

The company has a debt-to-equity ratio of 1.00, a current ratio of 7.22 and a quick ratio of 5.93.

Paradigm Biopharmaceuticals Company Profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.